Key preclinical milestone designed to establish safety profile and maximum tolerated dose for anticipated clinical trial of EB-373 CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a…
Presentations highlight research involving Enveric’s EVM301 Series of non-hallucinogenic neuroplastogens and the company’s lead product candidate, EB-373 CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology…
Thanks to the Golden Triangle, Britain is great at biotech innovation, it’s just not that good at nurturing this innovation through to the blue-chip stage. This can be attributed to…
The Psybrary™ portfolio includes numerous unique, previously unreported molecules, which are protected by Enveric’s expansive and growing intellectual property estate CAMBRIDGE, Mass. – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the…
A Boston-area biotechnology firm announced it has received a patent titled “Carboxylated Psilocybin Derivatives and Methods of Using” for its EVM301 series of molecules to treat a range of mental…
Ahead of the competition, drug developers are locking in patents while the psychedelic renaissance takes the medical community by storm. Full Article
Paper co-authored by Enveric researchers describes the discovery of a key cane toad enzyme and its application to the biosynthesis of novel indolethylamine-type drug candidates with potential use in psychiatric…
The psychedelic drug MDMA edges closer towards FDA approval for the treatment of post-traumatic stress disorder (PTSD) in the U.S., after promising results of a trial were published. This comes…
The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series…
Enveric Biosciences (NASDAQ: ENVB) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company’s…